Abstract:SUMMARY Eight children with symptoms of HIV infection were treated for 12-26 months (median 14 months) with infusions of intravenous immunoglobulin (200 mg/kg) every three weeks. Significant improvement was noted in all children in terms of weight gain, number of infectious episodes, and days spent in hospital. This resulted in a 49% saving in cost on treatment compared with costs accrued previously during inpatient admissions. Immunoglobulin concentrations, which were raised at the start of treatment were not… Show more
“…There was also a moderate improvement in CD4 counts and in mitogen responsiveness in the treated group compared to the control which showed deterioration during the course of the study. In a small, uncontrolled study, Haque et al (194) treated 8 HIVinfected children with 200 mgkgidose every 3 weeks for 12 to 26 months. After 12 months all had subjective improvement and fewer serious infections compared to the patients' own historical control period, but no control group was included.…”
“…There was also a moderate improvement in CD4 counts and in mitogen responsiveness in the treated group compared to the control which showed deterioration during the course of the study. In a small, uncontrolled study, Haque et al (194) treated 8 HIVinfected children with 200 mgkgidose every 3 weeks for 12 to 26 months. After 12 months all had subjective improvement and fewer serious infections compared to the patients' own historical control period, but no control group was included.…”
“…immuno globulins may have beneficial effects on HIV-1-infected patients. It has been claimed that treatment with immunoglobulin concentrates reduces the risk of disease progression [16,17], Thus, in our opinion, it is worth investi gating whether the relatively slow disease pro gression in patients treated with intermediatepurity factor VIII concentrate may be due to such an effect.…”
39 human immunodeficiency-virus-1 (HIV-1 )-positive hemophiliacs who had been regularly treated with non-virus-inactivated intermediate-purity factor VIII concentrates were divided into two groups. Group A consisted of 21 patients with a CD4/CD8 cell ratio of less than 1.0 and group B of 18 patients with a CD4/CD8 cell ratio of greater than 1.0. All patients of group A were switched to a high-purity virus-inactivated factor VIII concentrate, whereas patients of group B continued to receive the intermediate-purity concentrate. There was no significant difference in the average decline of CD4 cells between the two groups during the observation period. 9 patients of group A and 4 patients of group B developed AIDS. 5 patients of group A but 11 patients of group B remained clinically asymptomatic. We conclude that the 15-fold increase in purity of the factor VIII concentrate had no apparent beneficial effect on the CD4 cell counts in this patient group.
“…in sera were (1-65) g/l at the beginning and 23*16 (2 09) g/l after 24 months respectively. IgG concentration in sera of the control group were 22-16 (2-84) g/l at the entry and [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] (2126) g/l at the last examination.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.